Table 1 Association of MRD assessed... | American Society of Hematology

Table 1

Association of MRD assessed before the second course of therapy by qualitative PCR for NPM-ALK in BM or PB with clinical and biological characteristics of the ALCL among MDD-positive patients

		MDD-positive	MRD
		MDD-positive	Negative	Positive	n.a.	P‡
All patients		103	26	26	51
Skin	No	81	21 (81%)	20 (77%)	40	.73
	Yes	22	5 (19%)	6 (23%)	11
Mediastinum	No	38	8 (31%)	3 (12%)	27	.09
	Yes	65	18 (69%)	23 (88%)	24
Visceral organs*	No	57	18 (69%)	11 (42%)	28	.05
	Yes	46	8 (31%)	15 (58%)	23
CNS	No	93	25 (100%)	25 (96%)	43	.32
	Yes	7		1 (4%)	6
	n.a.	3	1		2
BM	Neg	89	22 (85%)	21 (81%)	46	.71
	Pos	14	4 (15%)	5 (19%)	5
Stage†	I	—				.31
	II	9	2 (8%)		7
	III	70	19 (73%)	19 (73%)	32
	IV	23	5 (19%)	7 (27%)	11
Histologic subtype	Common	39	17 (68%)	6 (26%)	16	.004
	Not common	42	8 (32%)	17 (74%)	17
	n.a.	22	1	3	18
ALK-AB titer	≤1/750	26	7 (32)	10 (59%)	9	.09
	>1/750	49	15 (68%)	7 (41%)	27
	n.a.	28	4	9	15

		MDD-positive	MRD
		MDD-positive	Negative	Positive	n.a.	P‡
All patients		103	26	26	51
Skin	No	81	21 (81%)	20 (77%)	40	.73
	Yes	22	5 (19%)	6 (23%)	11
Mediastinum	No	38	8 (31%)	3 (12%)	27	.09
	Yes	65	18 (69%)	23 (88%)	24
Visceral organs*	No	57	18 (69%)	11 (42%)	28	.05
	Yes	46	8 (31%)	15 (58%)	23
CNS	No	93	25 (100%)	25 (96%)	43	.32
	Yes	7		1 (4%)	6
	n.a.	3	1		2
BM	Neg	89	22 (85%)	21 (81%)	46	.71
	Pos	14	4 (15%)	5 (19%)	5
Stage†	I	—				.31
	II	9	2 (8%)		7
	III	70	19 (73%)	19 (73%)	32
	IV	23	5 (19%)	7 (27%)	11
Histologic subtype	Common	39	17 (68%)	6 (26%)	16	.004
	Not common	42	8 (32%)	17 (74%)	17
	n.a.	22	1	3	18
ALK-AB titer	≤1/750	26	7 (32)	10 (59%)	9	.09
	>1/750	49	15 (68%)	7 (41%)	27
	n.a.	28	4	9	15

ALK-AB titer, ALK-antibody titer; CNS, central nervous system; n.a., not available.

Liver, spleen, lung.

†

St. Jude staging system.

‡

For comparison of MRD-positive with MRD-negative patients.

View Large

This Feature Is Available To Subscribers Only